Related Experiment Video
Updated: Jan 15, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and
Julieanne Knupp1, Pedro Cardoso1, Katherine G Young1
1Department of Clinical and Biomedical Sciences, University of Exeter, Exeter, U.K.
Objective:
Selecting appropriate individuals for monogenic diabetes genetic testing is challenging. We aimed to develop a new probability calculator, integrating clinical features and biomarkers, to aid identification of monogenic diabetes.
Research Design And Methods:
We developed two prediction models (for early-insulin-treated, proxy for type 1 diabetes; and not-early-insulin-treated patients, proxy for type 2 diabetes) using a Bayesian recalibration mixture model approach. We used case-control data (monogenic diabetes = 594, non-monogenic diabetes = 597) for initial model development (clinical features only) and recalibrated to population data (Using pharmacogeNetics to Improve Treatment in Early-onset Diabetes [UNITED] study, n = 1,299) including biomarkers (C-peptide and islet autoantibodies). We externally validated the calculator in an independent population-based cohort (n = 1,025).
Results:
For early-insulin-treated individuals, the model incorporating biomarkers improved discrimination over using clinical features only (receiver operating characteristic area under the curve [ROCAUC] 0.98 [95% credible interval [CrI] 0.95-0.98] vs. 0.80 [95% CrI 0.71-0.82], P < 0.001) or biomarkers alone (ROCAUC 0.96 [95% CI 0.95-0.97]). For not-early-insulin-treated participants, the calculator showed good discrimination (ROCAUC 0.86 [95% CrI 0.85-0.88]). Both models calibrated well and showed good discrimination in external validation (ROCAUC 0.98 [95% CrI 0.98-0.98] and 0.92 [95% CrI 0.90-0.93] for early- and not-early-insulin-treated individuals, respectively). Using a ≥5% probability threshold to guide testing achieved positive test rates for monogenic diabetes of 16-19%.
Conclusions:
We developed an updated monogenic diabetes probability calculator that integrates both clinical features and biomarkers, providing greater discrimination than using clinical features or biomarkers alone and providing appropriate measures for selecting individuals for monogenic diabetes diagnostic testing. This is now available as an online calculator and has immediate clinical utility for White European individuals diagnosed with diabetes ≤35 years.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications

